TREPROSTINIL SODIUM

Treprostinil sodium is a soluble salt for parenteral or inhaled formulations with identical pulmonary vasodilatory effects. Side effects include cough, nausea, edema, and pain at infusion sites.

SKU: ebd216406ac2 Category: Tag:

Product Description


Mechanism of Action

TREPROSTINIL SODIUM (ID 27729) demonstrates a multi‑layer biochemical interaction architecture integrating high‑bandwidth signalling interference, catalytic‑domain perturbation, mitochondrial‑network recalibration, ion‑flux redistribution, cytoskeletal restructuring, membrane‑potential modulation and transcription‑factor pathway realignment. Its molecular conformation enables docking to catalytic residues, allosteric nodes, transmembrane helices, nucleotide‑binding pockets, redox‑buffer centres and polymeric scaffolding complexes, providing system‑wide influence across metabolic, electrophysiological, structural and genomic domains.

At the signalling stratum, TREPROSTINIL SODIUM may reshape phosphorylation landscapes, alter the propagation kinetics of ERK, MAPK, JNK and p38 pathways, modulate PI3K–AKT survival gating, adjust G‑protein coupling efficiency, redistribute Ca²⁺ microdomains, influence IP₃/DAG signalling geometry, and redefine cAMP‑PKA amplitude. Mitochondrial effects include ETC‑complex rebalancing, ATP/ADP cycle remapping, ROS‑threshold displacement, membrane‑potential polarity modulation and cross‑organelle stress signalling.

High‑Precision Research Applications

  • Kinome‑scale cascade interference mapping & catalytic‑pathway reconstruction
  • High‑resolution docking, ligand‑meta‑stability tracking & conformational‑flow modelling
  • UPR/ER‑stress, mitophagy and organelle cross‑talk quantification
  • Multi‑omics regulatory‑network reconstruction (RNA‑seq, metabolomics, phosphoproteomics, proteomics)
  • Cytoskeletal mechanics including actin/tubulin turnover and force‑distribution modelling
  • Cell‑fate simulations across apoptosis, necroptosis, ferroptosis & parthanatos pathways
  • AI‑enhanced SAR/QSAR optimisation engines for predictive compound modelling

Toxicodynamics & Cellular Hazard Spectrum

  • Acute ROS surge and antioxidant‑buffer saturation
  • Mitochondrial fragmentation or ETC‑axis collapse
  • Severe Na⁺/K⁺/Ca²⁺ ion‑homeostasis destabilisation
  • Cytoskeletal depolymerisation & structural‑integrity failure
  • Membrane‑tension breakdown & lipid‑bilayer thinning
  • Hyperactivation of inflammatory master regulators (NF‑κB, STAT, IRF families)
  • Activation of multiple programmed‑cell‑death pathways
  • Epigenetic drift including methylation and acetylation instability

For expert laboratory use only — not intended for biological or therapeutic exposure.

Datasheet


Molecular Formula

C23H33NaO5

Molecular Weight

412.5 g/mol

CAS Number

695-793-9

Storage Condition

Store in a cool, dry place. Keep container tightly closed. Protect from moisture and light.

Solubility

Solubility depends on solvent and conditions (e.g., pH). Please contact us for solvent-specific guidance.

Purity

Purity information is available upon request (COA).

Synonym

Treprostinil sodium; YUTREPIA; 7JZ75N2NT6; CHEBI:50863; Acetic acid, (((1R,2R,3aS,9aS)-2,3,3a,4,9,9a-hexahydro-2-hydroxy-1-((3S)-3-hydroxyoctyl)-1H-benz(f)inden-5-yl)oxy)-, monosodium salt

IUPAC/Chemical Name

sodium 2-[[(1R,2R,3aS,9aS)-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[g]naphthalen-5-yl]oxy]acetate

InChl Key

IQKAWAUTOKVMLE-ZSESPEEFSA-M

InChl Code

InChI=1S/C23H34O5.Na/c1-2-3-4-7-17(24)9-10-18-19-11-15-6-5-8-22(28-14-23(26)27)20(15)12-16(19)13-21(18)25;/h5-6,8,16-19,21,24-25H,2-4,7,9-14H2,1H3,(H,26,27);/q;+1/p-1/t16-,17-,18+,19-,21+;/m0./s1

References

https://pubchem.ncbi.nlm.nih.gov/compound/23663413;

3D Conformer.

(Click, turn or enlarge)

Download our GMP API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

Download